← All diseases

Eye and hearing diseases

Retinitis pigmentosa (RP)

An inherited disease that affects the retina, the light-sensing layer at the back of the eye. Night vision is the first to get worse. The field of vision narrows over the years.

Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source

This page is translated from the Turkish original.

This disease is followed through the “Eye and hearing diseases” group.

Understanding the disease

This section has not yet been reviewed by a physician. It summarises patient information from sources such as MedlinePlus, Orphanet and the NHS in plain language. The disease can differ from person to person; talk to your doctor about diagnosis and treatment.

What happens in this disease?

The retina is a thin layer at the back of the eye that senses light. It contains light cells called rods and cones. In RP, these cells slowly break down. First the rods, which allow vision in the dark, are affected, then the cones. Sometimes RP is part of a syndrome together with other problems such as hearing loss.

Which symptoms can occur?

Symptoms usually begin in childhood or young adulthood. How fast vision is lost varies from person to person.

  • Difficulty seeing at night and in dim light (first symptom)
  • Loss of side vision, over time tunnel vision
  • Discomfort from bright light
  • Reduced color vision
  • In later stages, central vision also gets worse; reading and recognizing faces become difficult
  • Additional eye problems such as cataract or fluid build-up in the retina

How is it diagnosed?

The eye doctor widens the pupil with drops and looks at the retina. A visual field test measures side vision. A test called ERG measures how the retina responds to light. OCT takes a detailed picture of the retina. A genetic test helps to find out the type of RP.

Treatment and care

There is not yet a treatment that stops most types of RP. For people with low vision, aids and vision training help them make the best use of their remaining sight. Some vitamin supplements may slow the loss. But too much can be harmful, so it is necessary to ask the doctor. Regular eye checks catch additional problems such as cataract early. Sunglasses protect the eyes from light. There is an approved gene therapy for a small group with two changes in the RPE65 gene. Research on gene, cell and drug therapies is ongoing. The doctor who follows the disease decides which treatment is suitable.

For the family: inheritance and genetic counselling

RP can be inherited in different ways. In the dominant type, the chance of passing it from an affected parent to a child is 1 in 2 in each pregnancy. In the recessive type, the chance of an affected child for a carrier couple in each pregnancy is 1 in 4. Recessive types may be more likely when parents are related by blood. In the X-linked type, mostly males are affected. Genetic counselling explains the type and the risk in the family.

Source: MedlinePlus Genetics: Retinitis pigmentosa · National Eye Institute (NIH): Retinitis Pigmentosa · NORD: Retinitis Pigmentosa

Key facts

How common is it?
Prevalence: 1-5 per 10 000 (Worldwide)
How is it inherited?
Autosomal dominant · Autosomal recessive · Mitochondrial inheritance · X-linked recessive
When does it usually start?
Adolescence, Adulthood, Childhood
Gene(s) involved
HKDC1, FSD1L, SAXO6, RNU6-1, RNU6-2, RNU6-8

These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.

You are not alone: patient associations in Türkiye

Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.

We could not find a patient association specific to this disease.

For all rare diseases: Nadir Hastalıklar Federasyonu

Support and help

Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.

News about Retinitis (RP)

Clinical trials (ClinicalTrials.gov)

A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.

This list is not a treatment recommendation. Treatments tested in phase 1–3 trials are investigational (experimental): their efficacy and safety have not yet been proven and they are not approved treatments. Taking part depends on each trial’s criteria and a physician’s assessment; the first step is to talk to the doctor who manages your care.

Questions you can ask your doctor

  • Could this trial be suitable for us?
  • If we take part, how would current treatment and check-ups be affected?
  • Where does the trial take place, and how are travel and accommodation handled?
  • What happens if we want to leave the trial?

ClinicalTrials.gov lists 67 active interventional studies for this disease. 24 are recruiting now; none has a site in Türkiye. Last checked: October 7, 2026.

Selected records (studies with a site in Türkiye first):

See all studies on ClinicalTrials.gov · Joining clinical trials

Eye and hearing diseases: other news

Medical codes (for talking with your doctor and finding sources)

These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.

Orphanet code: ORPHA:791

No separate ICD-11 code; WHO classifies this disease under: 9B70

Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.

This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.

The information on these pages is for general information only and does not replace medical advice. Talk to your doctor about diagnosis and treatment decisions. In an emergency in Türkiye, call 112.

Every update is based on an open source and labeled with its level of evidence. No advertising and no drug brand names. Our scientific principles

This page was translated from Turkish by the Doktorclub editorial team.